

Molecular Design and Synthesis of Ivermectin

Hybrids Targeting Hepatic and Erythrocytic

Stages of *Plasmodium* Parasites

Lovepreet Singh,^a Diana Fontinha,^b Denise Francisco,^b Antonio M. Mendes,^b Miguel Prudêncio^b and Kamaljit Singh^{a,*}

^aDepartment of Chemistry, Guru Nanak Dev University, Amritsar – 143 005, India

^bInstituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal

Table of Contents		
Sr. No.	Content	Page number
1.	Figure S1: ¹ H and ¹³ C NMR spectra of 3 .	3
2.	Figure S2: ¹ H and ¹³ C NMR spectra of 5 .	4
3.	Figure S3: ¹ H and ¹³ C NMR spectra of 6 .	5
4.	Figure S4: ¹ H and ¹³ C NMR spectra of 10a .	6
5.	Figure S5: ¹ H and ¹³ C NMR spectra of 10b .	7
6.	Figure S6: ¹ H and ¹³ C NMR spectra of 11 .	8
7.	Figure S7: ¹ H and ¹³ C NMR spectra of 12 .	9
8.	Figure S8: ¹ H and ¹³ C NMR spectra of 13 .	10
9.	Figure S9: ¹ H and ¹³ C NMR spectra of 14 .	11
10.	Figure S10: ¹ H and ¹³ C NMR spectra of 15 .	12
11.	Figure S11: ¹ H and ¹³ C NMR spectra of 16 .	13
12.	Figure S12: ¹ H and ¹³ C NMR spectra of 17 .	14
13.	Figure S13: ¹ H and ¹³ C NMR spectra of 18 .	15
14.	Figure S14: ¹ H and ¹³ C NMR spectra of 19 .	16
15.	Figure S15: ¹ H and ¹³ C NMR spectra of 20 .	17

16.	Figures S16 and S17: I.R. spectra of 3 and 5 .	18
17.	Figures S18 and S19: I.R. spectra of 6 and 10a .	19
18.	Figures S20 and S21: I.R. spectra of 10b and 11 .	20
19.	Figures S22 and S23: I.R. spectra of 12 and 13 .	21
20.	Figures S24 and S25: I.R. spectra of 14 and 15 .	22
21.	Figures S26 and S27: I.R. spectra of 16 and 17 .	23
22.	Figures S28 and S29: I.R. spectra of 18 and 19 .	24
23.	Figure S30: I.R. spectrum 20 .	25
24.	Figures S31 and S32: HRMS of 3 and 5 .	26
25.	Figures S33 and S34: HRMS of 6 and 10a .	27
26.	Figures S35 and S36: HRMS of 10b and 11 .	28
27.	Figures S37 and S38: HRMS of 12 and 13 .	29
28.	Figures S39 and S40: HRMS of 14 and 15 .	30
29.	Figures S41 and S42: HRMS of 16 and 17 .	31
30.	Figures S43 and S44: HRMS of 18 and 19 .	32
31.	Figure S45: HRMS of 20 .	33
32.	Figure S46: Assessment of <i>in vitro</i> activity of ivermectin derivatives against the hepatic stage of <i>P. berghei</i> infection.	34
33.	Figure S47: Mouse survival following spz administration and treatment	34
30.	Figure S48: HPLC chromatograph of 1 .	35
31.	Figure S49: HPLC chromatograph of 3 .	36
32.	Figure S50: HPLC chromatograph of 16 .	37
33.	Figure S51: HPLC chromatograph of 18 .	38
34.	Figure S52: HPLC chromatograph of 19 .	39
35.	Figure S53: HPLC chromatograph of 20 .	40
36.	Figure S54: ¹ H and ¹³ C NMR spectra of 22 .	41
37.	Figure S55: ¹ H and ¹³ C NMR spectra of 23 .	42
38.	Figure S56 and S57: HRMS of 22 and 23 .	43
39.	Figures S58 and S59: I.R. spectra of 22 and 23 .	44
40.	Procedure for docking studies	45
41.	Molecular strings and biological data	46





Figure S1. ¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (125 MHz, CDCl₃) of **3**.




Figure S2. ¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) of 5.




Figure S3. ¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) of **6**.




Figure S4. ¹H NMR (300 MHz, CDCl₃) and ¹³C NMR (75 MHz, CDCl₃) of **10a**.




Figure S5. ^1H NMR (300 MHz, CDCl_3) and ^{13}C NMR (75 MHz) **10b**.




Figure S6. ¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (125 MHz, CDCl₃) of **11**.




Figure S7. ¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (125 MHz, CDCl₃) of **12**





Figure S8. ^1H NMR (500 MHz, CDCl_3) and ^{13}C NMR (125 MHz, CDCl_3) of **13**.






Figure S10. ^1H NMR (400 MHz, CDCl_3) and ^{13}C NMR (100 MHz, CDCl_3) of **15**.




Figure S12. ¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (125 MHz, CDCl₃) of 17.




Figure S13. ^1H NMR (500 MHz, CDCl_3) and ^{13}C NMR (125 MHz, CDCl_3) of **18**.




Figure S14. ¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (125 MHz, CDCl₃) of **19**.




Figure S15. ¹H NMR (500 MHz, CDCl₃) and ¹³C NMR (125 MHz, CDCl₃) of **20**.




Figure S16: IR spectrum of **3**.




Figure S17: IR spectrum of **5**.




Figure S18: IR spectrum of **6**.




Figure S19: IR spectrum of **10a**.




Figure S20: IR spectrum of **10b**.




Figure S21: IR spectrum of **11**.




Figure S22: IR spectrum of **12**.




Figure S23: IR spectrum of **13**.




Figure S24: IR spectrum of **14**.




Figure S25: IR spectrum of **15**.




Figure S26: IR spectrum of 16.




Figure S27: IR spectrum of 17




Figure S28: IR spectrum of **18**.




Figure S29: IR spectrum of **19**.




Figure S30: IR spectrum of **20**.




Figure S31: HRMS of **3**.




Figure S32: HRMS of **5**.




Figure S33: HRMS of **6**.




Figure S34: HRMS of **10a**.




Figure S35: HRMS of 10b.




Figure S36: HRMS of 11




Figure S37: HRMS of 12




Figure S38: HRMS of 13.




Figure S39: HRMS of 14.




Figure S40: HRMS of 15.




Figure S41: HRMS of 16.




Figure S42: HRMS of 17.




Figure S43: HRMS of **18**.




Figure S44: HRMS of **19**.




Figure S45: HRMS of **20**.




Figure S46: Assessment of *in vitro* activity of LP compounds/ivermectin derivatives against the hepatic stage of *P. berghei* infection. Total parasite load (infection scale, bars) and cell viability (cell confluency scale, dots) are shown. Results were normalized to the negative control, the drug vehicle dimethyl sulphoxide (DMSO), and are represented as mean $\pm$ SD, n = 1.





Figure S47: Mouse survival following spz administration and treatment using 19 and 3. (Red line: DMSO; Light grey: 19; Dark grey: 3.)

Area % Report

Data File: C:\EZChrom Elite\Enterprise\Projects\Default\Data\IVM R1 f 28-08-2019
 Method: C:\EZChrom Elite\Enterprise\Projects\Default\Method\Baldev Singh\IAA Final
 method\ABA.met
 Acquired: 8/28/2019 7:30:18 PM
 Printed: 8/29/2019 3:51:14 PM




**DAD: Signal A,
 245 nm/Bw:2 nm
 Ref 400
 nm/Bw:50 nm
 Results**

Retention Time	Area	Area %	Height	Height %
1.940	39272	0.07	7368	0.57
2.167	5537	0.01	1341	0.10
2.493	160894	0.30	23220	1.78
2.873	36109	0.07	4144	0.32
3.567	35780	0.07	3640	0.28
4.000	42927	0.08	3813	0.29
7.333	107241	0.20	11779	0.90
7.487	68704	0.13	5975	0.46
8.960	192087	0.36	9036	0.69
12.247	1254617	2.36	38987	2.99
16.193	49806716	93.64	1169744	89.81
20.973	256022	0.48	5689	0.44
22.260	1045411	1.97	15747	1.21
24.933	39467	0.07	734	0.06
31.280	100430	0.19	1300	0.10
Totals	53191214	100.00	1302517	100.00

Figure S48. HPLC chromatograph of **1**.

Area % Report

Data File: C:\EZChrom Elite\Enterprise\Projects\Default\Data\Sample 3 16-10-2019
 Method: C:\EZChrom Elite\Enterprise\Projects\Default\Method\untitled.met
 Acquired: 10/16/2019 1:41:07 PM
 Printed: 10/18/2019 5:52:07 PM




**DAD: Signal A,
 245 nm/Bw:2 nm
 Ref 400
 nm/Bw:50 nm
 Results**

Retention Time	Area	Area %	Height	Height %
3.640	1823847	2.73	173782	3.20
4.413	63404712	94.74	5133048	94.43
5.387	716779	1.07	59849	1.10
5.900	982134	1.47	69321	1.28
Totals	66927472	100.00	5436000	100.00

Figure S49. HPLC chromatograph of **3**.

Area % Report

Data File: C:\EZChrom Elite\Enterprise\Projects\Default\Data\Sample 16 16-10-2019
 Method: C:\EZChrom Elite\Enterprise\Projects\Default\Method\untitled.met
 Acquired: 10/16/2019 2:28:01 PM
 Printed: 10/18/2019 5:55:21 PM



DAD: Signal A,
245 nm/Bw:2 nm
Ref 400
nm/Bw:50 nm


Results

Retention Time	Area	Area %	Height	Height %
2.560	109998	0.37	15500	1.78
3.987	136832	0.46	10690	1.23
10.240	419195	1.40	13940	1.60
13.300	29234535	97.77	831055	95.39
Totals	29900560	100.00	871185	100.00

Figure S50. HPLC chromatograph of **16**.

Area % Report

Data File: C:\EZChrom Elite\Enterprise\Projects\Default\Data\Sample 18 16-10-2019
 Method: C:\EZChrom Elite\Enterprise\Projects\Default\Method\untitled.met
 Acquired: 10/16/2019 4:01:48 PM
 Printed: 10/18/2019 5:44:15 PM




DAD: Signal A,
 245 nm/Bw:2 nm
 Ref 400
 nm/Bw:50 nm
 Results

Retention Time	Area	Area %	Height	Height %
10.373	1022971	4.49	44295	6.71
11.173	200795	0.88	6277	0.95
14.253	21567186	94.63	609596	92.34
Totals	22790952	100.00	660168	100.00

Figure S51. HPLC chromatograph of **18**.

Area % Report

Data File: C:\EZChrom Elite\Enterprise\Projects\Default\Data\sample 19 chem 22-10-19.dat
 Method: C:\EZChrom Elite\Enterprise\Projects\Default\Method\untitled.met
 Acquired: 10/22/2019 4:32:28 PM
 Printed: 10/23/2019 12:05:37 PM



DAD: Signal A,
245 nm/Bw:2 nm
Ref 400
nm/Bw:50 nm
Results


Retention Time	Area	Area %	Height	Height %
3.500	204172	0.34	19488	0.73
4.267	384909	0.64	30151	1.13
5.047	256402	0.43	12753	0.48
5.893	1903977	3.16	128653	4.80
7.873	56590922	94.00	2451386	91.48
9.680	864158	1.44	37263	1.39

Totals	60204540	100.00	2679694	100.00
--------	----------	--------	---------	--------

Figure S52. HPLC chromatograph of **19**.

Area % Report



Data File: C:\EZChrom Elite\Enterprise\Projects\Default\Data\sample 20 18-10-19.dat
 Method: C:\EZChrom Elite\Enterprise\Projects\Default\Method\untitled.met
 Acquired: 10/18/2019 1:08:46 PM
 Printed: 10/18/2019 5:48:19 PM





DAD: Signal A,
245 nm/Bw:2 nm
Ref 400
nm/Bw:50 nm
Results

Retention Time	Area	Area %	Height	Height %
8.760	545137	1.69	28759	2.66
9.500	258482	0.80	14575	1.35
9.873	249417	0.77	14191	1.31
12.113	30317009	94.06	998675	92.20
13.580	861735	2.67	26975	2.49
Totals	32231780	100.00	1083175	100.00


Figure S53. HPLC chromatograph of **20**.




FigureS54. ¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) of 22.



FigureS55. ¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) of **23**.



FigureS56: HRMS of 22.



FigureS57: HRMS of 23.




Figure S58: IR spectrum of 22.




Figure S59: IR spectrum of 23.

Procedure for Molecular docking studies

The 2D structure of the ligand was drawn using 2D sketcher (Schrödinger_Suites_2019-3, LLC, New York, 2019). The 3D structure of the ligand with the lowest energy was generated using LigPrep module of Schrödinger. The correct ionization states (pH 7.0±2.0) of the ligand was generated and optimized with default settings (Ligprep, Schrödinger_Suites_2019-3). The 3D crystal structure of *C. elegans* Glutamate-gated chloride channel (GluCl) in complex with Fab and Ivermectin (PDB ID:3RHW; resolution 3.26 Å) was retrieved from protein data bank (www.rcsb.org). The proteins were prepared for docking using Protein Preparation Wizard (Maestro 12.1, Schrödinger_Suites_2019-3). Further to refine the structure, OPLS-3E force field parameter was used to alleviate steric clashes. The location of co-crystallized ligand Ivermectin was used to choose the center and size of the receptor grid, which was generated using Glide (Schrödinger_Suites_2019-3, LLC, New York, 2019) with default settings for all parameters. The grid size was chosen sufficiently large to include all active site residues involved in substrate binding. The ligand was docked to the receptor grid file (GluCl) using Glide Standard precision (SP) mode. Default settings were used for the refinement and scoring.

Compound number	Smiles	Antiplasmodial activity	
		IC ₅₀ (μM) <i>P. berghei</i>	IC ₅₀ (nM) <i>PfNF54</i>
3	<chem>O=C([C@@H]1C=C(C)C(O)[C@]2([H])[C@@]1(O)/C(CO2)=C/C=C/[C@H](C)[C@H](O)/C(C)=C/C3)O[C@H]4C[C@]3([H])O[C@]5(O[C@H]([C@H](C)CC)[C@@H](C)CC5)C4</chem>	4.557 ± 1.981	
5	<chem>O=C([C@@H]1C=C(C)C(O[Si](C)(C)C(C)(C)[C@]2([H])[C@@]1(O)/C(CO2)=C/C=C/[C@H](C)[C@H](O)/C(C)=C/C3)O[C@H]4C[C@]3([H])O[C@]5(O[C@H]([C@H](C)CC)[C@@H](C)CC5)C4</chem>		
6	<chem>O=C([C@@H]1C=C(C)C(O[Si](C)(C)C(C)(C)[C@]2([H])[C@@]1(O)/C(CO2)=C/C=C/[C@H](C)[C@H](OC(CCl)=O)/C(C)=C/C3)O[C@H]4C[C@]3([H])O[C@]5(O[C@H]([C@H](C)CC)[C@@H](C)CC5)C4</chem>		
7	<chem>O=C([C@@H]1C=C(C)C(O[Si](C)(C)C(C)(C)[C@]2([H])[C@@]1(O)/C(CO2)=C/C=C/[C@H](C)[C@H](OC(CN=[N+]=[N-])=O)/C(C)=C/C3)O[C@H]4C[C@]3([H])O[C@]5(O[C@H]([C@H](C)CC)[C@@H](C)CC5)C4</chem>		
8	<chem>[Fe].C#Cc1cccc1.c2cccc2</chem>		
9	<chem>[Fe].C#CC(C=C1)=CC=C1c2cccc2.c3cccc3</chem>		
10a	<chem>O=C(OC(C)C)C1=C(C)N=C(OCC#C)N=C1C2=CC=CC([N+])([O-])=O=C2</chem>		
10b	<chem>O=C(OCC)C1=C(C)N=C(OCC#C)N=C1C2=C([N+])([O-])=O)C=C(OC)C(OC)=C2</chem>		
10c	<chem>O=C(OCC)C1=C(C)N=C(OCC#C)N=C1C2=CC=CC=C2</chem>		
11	<chem>O=C([C@@H]1C=C(C)C(O[Si](C)(C)C(C)(C)[C@]2([H])[C@@]1(O)/C(CO2)=C/C=C/[C@H](C)[C@H](OC(CN3C=C(c4cccc4)N=N3)=O)/C(C)=C/C5)O[C@H]6C[C@]5([H])O[C@]7(O[C@H]([C@H](C)CC)[C@@H](C)CC7)C6.[Fe].c8cccc8</chem>		
12	<chem>O=C([C@@H]1C=C(C)C(O[Si](C)(C)C(C)(C)[C@]2([H])[C@@]1(O)/C(CO2)=C/C=C/[C@H](C)[C@H](OC(CN3C=C(C(C=C4)=CC=C4c5cccc5)N=N3)=O)/C(C)=C/C6)O[C@H]7C[C@]6([H])O[C@]8(O[C@H]([C@H](C)CC)[C@@H](C)CC8)C7.[Fe].c9cccc9</chem>		
13	<chem>O=C(OC(C)C)C1=C(C)N=C(OCC(N=N2)=CN2CC(O[C@@H]([C@@H](C)/C=C/C=C(CO3)/[C@]4(O)[C@@]3([H])C(O[Si](C)(C)(C)C(C)C(C)=C[C@H]4C(O5)=O)/C(C)=C/C[C@]6([H])C[C@H]5C[C@@]7(O[C@H]([C@H](C)CC)[C@@H](C)CC7)O6)=O)N=C1C8=CC=CC([N+])([O-])=O=C8</chem>		
14	<chem>O=C(OCC)C1=C(C)N=C(OCC(N=N2)=CN2CC(O[C@@H]([C@@H](C)/C=C/C=C(CO3)/[C@]4(O)[C@@]3([H])C(O[Si](C)(C)(C)C(C)C(C)=C[C@H]4C(O5)=O)/C(C)=C/C[C@]6([H])C[C@H]5C[C@@]7(O[C@H]([C@H](C)CC)[C@@H](C)CC7)O6)=O)N=C1C8=C([N+])([O-])=O)C=C(OC)C(OC)=C8</chem>		
15	<chem>O=C(OCC)C1=C(C)N=C(OCC(N=N2)=CN2CC(O[C@@H]([C@@H](C)/C=C/C=C(CO3)/[C@]4(O)[C@@]3([H])C(O[Si](C)(C)(C)C(C)C(C)=C[C@H]4C(O5)=O)/C(C)=C/C[C@]6([H])C[C@</chem>		

	H]5C[C@@]7(O[C@H]([C@H](C)CC)[C@@H](C)CC7)O6)=O)N=C1C8=CC=CC=C8		
16	O=C([C@@H]1C=C(C)C(O)[C@]2([H])[C@@]1(O)/C(CO2)=C /C=C/[C@H](C)[C@H](OC(CN3C=C(c4cccc4)N=N3)=O)/C(C) =C/C5)O[C@H]6C[C@]5([H])O[C@]7(O[C@H]([C@H](C)CC)[C@@H](C)CC7)C6.[][Fe][].c8cccc8	0.990 ± 0.068	256.7 ± 46.6
17	O=C([C@@H]1C=C(C)C(O)[C@]2([H])[C@@]1(O)/C(CO2)=C /C=C/[C@H](C)[C@H](OC(CN3C=C(C(C=C4)=CC=C4c5cccc5) N=N3)=O)/C(C)=C/C6)O[C@H]7C[C@]6([H])O[C@]8(O[C@ H]([C@H](C)CC)[C@@H](C)CC8)C7.[][Fe][].c9cccc9		
18	O=C(OC(C)C1=C(C)N=C(OCC(N=N2)=CN2CC(O[C@@H]([C@ @@H](C)/C=C/C=C(CO3)/[C@]4(O)[C@@]3([H])C(O)C(C)=C [C@H]4C(O5)=O)/C(C)=C/C[C@]6([H])C[C@H]5C[C@@]7(O [C@H]([C@H](C)CC)[C@@H](C)CC7)O6)=O)N=C1C8=CC=CC ([N+])([O-])=O)=C8	0.911 ± 0.076	161.2 ± 40.49
19	O=C(OCC)C1=C(C)N=C(OCC(N=N2)=CN2CC(O[C@@H]([C@ @@H](C)/C=C/C=C(CO3)/[C@]4(O)[C@@]3([H])C(O)C(C)=C [C@H]4C(O5)=O)/C(C)=C/C[C@]6([H])C[C@H]5C[C@@]7(O [C@H]([C@H](C)CC)[C@@H](C)CC7)O6)=O)N=C1C8=C([N+] [O-])=O)C=C(OC)C(OC)=C8	0.503 ± 0.002	50.2 ± 24.5
20	O=C(OCC)C1=C(C)N=C(OCC(N=N2)=CN2CC(O[C@@H]([C@ @@H](C)/C=C/C=C(CO3)/[C@]4(O)[C@@]3([H])C(O)C(C)=C [C@H]4C(O5)=O)/C(C)=C/C[C@]6([H])C[C@H]5C[C@@]7(O [C@H]([C@H](C)CC)[C@@H](C)CC7)O6)=O)N=C1C8=CC=CC= C8	0.990 ± 0.050	110.5 ± 64
21	O=C(OCC)C1=C(C)NC(NC1C2=CC=C(OC)C(OC)=C2)=O		
22	O=C(OCC)C1=C(C)NC(N=C1C2=C([N+])([O-])=O)C=C(OC)C(OC)=C2)=O		
23	O=C(OCC)C1=C(C)N=C(Cl)N=C1C2=C([N+])([O-])=O)C=C(OC)C(OC)=C2		